

Form PTO-1449 (modified)	Atty. Docket No.: DFCI:006US	Serial No.: 10/598,295
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant: Donald W. KUFÉ Surender KHARBANDA	
	Filing Date: April 5, 2007	Group: 1635
U.S. Patent Documents See Page 1-2	Foreign Patent Documents See Page 2	Other Art See Page 3-19

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	10/553,028	10/11/05	Belmares <i>et al.</i>	514	018	10/11/05
	A2	2002/0110841	08/15/02	Kufe	435	7.23	12/26/01
	A3	2003/0148969	08/07/03	Dobie <i>et al.</i>	514	44	12/20/01
	A4	2004/0018181	01/29/04	Kufe <i>et al.</i>	424	93.21	05/29/03
	A5	2004/0166543	08/26/04	Kufe	435	7.23	12/11/03
	A6	2004/0209832	10/21/04	McSwiggen	514	44	09/23/03
	A7	2005/0042209	02/24/05	Kufe <i>et al.</i>	424	93.21	02/13/04
	A8	2005/0053606	03/10/05	Kufe <i>et al.</i>	424	155.1	09/11/01
	A9	5,506,343	04/09/96	Kufe	530	387.7	10/25/94
	A10	5,530,101	06/25/96	Queen <i>et al.</i>	530	387.3	12/19/90
	A11	5,612,895	03/18/97	Balaji <i>et al.</i>	702	19	04/21/95
	A12	5,766,833	06/16/98	Balance <i>et al.</i>	435	69.7	11/17/93
	A13	5,776,427	07/07/98	Thorpe <i>et al.</i>	424	1.49	06/01/95
	A14	5,801,154	09/01/98	Baracchini <i>et al.</i>	514	44	04/08/97
	A15	5,861,381	01/19/99	Chambon <i>et al.</i>	514	44	06/07/95
	A16	5,998,148	12/07/99	Bennett <i>et al.</i>	435	6	04/08/99
	A17	6,020,363	02/01/00	Hirano <i>et al.</i>	514	456	12/17/98
	A18	6,054,438	04/25/00	Taylor-Papadimitiou <i>et al.</i>	514	44	06/01/95
	A19	6,074,841	06/13/00	Gearing <i>et al.</i>	435	69.1	11/19/96
	A20	6,222,020	04/24/01	Taylor-Papadimitriou <i>et al.</i>	530	395	06/01/95
	A21	6,589,921	07/08/03	Herrmann <i>et al.</i>	514	456	02/27/01
	A22	6,716,627	04/06/04	Dobie	435	375	12/20/01

25794698.1

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SM/

Form PTO-1449 (modified)		Atty. Docket No.: DFCI:006US	Serial No.: 10/598,295
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Donald W. KUFÉ Surender KHARBANDA	
		Filing Date: April 5, 2007	Group: 1635
U.S. Patent Documents See Page 1-2	Foreign Patent Documents See Page 2	Other Art See Page 3-19	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A23	60/308,307	07/27/01	Kufe			07/27/01
	A24	60/502,111	09/11/03	Jecminek <i>et al.</i>			09/11/03

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language
	B1	EP 1103623	07/01/98	Europe	English
	B2	WO 00/25827	05/11/00	WIPO	English
	B3	WO 00/34468	06/15/00	WIPO	English
	B4	WO 00/77031	12/21/00	WIPO	English
	B5	WO 01/12217	02/22/01	WIPO	English
	B6	WO 01/18035	03/15/01	WIPO	English
	B7	WO 01/57068	08/09/01	WIPO	English
	B8	WO 02/058450	08/01/02	WIPO	English
	B9	WO 02/22685	03/21/02	WIPO	English
	B10	WO 02/31512	04/18/02	WIPO	English
	B11	WO 03/014303	02/20/03	WIPO	English
	B12	WO 03/088995	10/30/03	WIPO	English
	B13	WO 2004/044160	05/27/04	WIPO	English
	B14	WO 2004/092339	10/28/04	WIPO	English
	B15	WO 93/20841	10/28/93	WIPO	English
	B16	WO 96/03502	02/08/96	WIPO	English

25794698.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SM/

Form PTO-1449 (modified)	Atty. Docket No.: DFCI:006US	Serial No.: 10/598,295
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant: Donald W. KUFÉ Surender KHARBANDA	
	Filing Date: April 5, 2007	Group: 1635
U.S. Patent Documents See Page 1-2	Foreign Patent Documents See Page 2	Other Art See Page 3-19

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Adams and Cory, "The Bcl-2 Protein Family: Arbiters of Cell Survival," <i>Science</i> , 281:1322-1326, 1998.
	C2	Agrawal and Kandimalla, "Antisense therapeutics: is it as simple as complementary base recognition?" <i>Molecular Medicine Today</i> , 6:72-81, 2000.
	C3	Akagi <i>et al.</i> , "CA19-9 epitope a possible marker for MUC-1/Y protein," <i>Int. J. Oncol.</i> , 18:1085-1091, 2001.
	C4	Ashkenazi and Dixit, "Apoptosis control by death and decoy receptors," <i>Curr. Opin. Cell Biol.</i> , 11:255-260, 1999.
	C5	Ashkenazi and Dixit, "Death Receptors: Signaling and Modulation," <i>Science</i> , 281:1305-1308, 1998.
	C6	Ashkenazi <i>et al.</i> , "Safety and antitumor activity of recombinant soluble Apo2 ligand," <i>J. Clin. Invest.</i> , 104:155-162, 1999.
	C7	Backstrom <i>et al.</i> , "Recombinant MUC1 mucin with a breast cancer-like O-glycosylation produced in large amounts in Chinese-hamster ovary cells," <i>Biochemical Journal</i> , 376:677-686, 2003.
	C8	Banerjee, "Omega amino acids in peptide design: incorporation into helices," <i>Biopolymers</i> , 39:769-77, 1996.
	C9	Barry and Sharkey, "Observer reproducibility during computer-assisted planimetric measurements of nuclear features," <i>Hum. Pathol.</i> , 16:225-7, 1985.
	C10	Barry <i>et al.</i> , "Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia," <i>Biochemical Pharmacology</i> , 40:2353-2362, 1990.
	C11	Baruch <i>et al.</i> , "Preferential expression of novel MUC1 tumor antigen isoforms in human epithelial tumors and their tumor-potentiating function," <i>Int. J. Cancer</i> , 71:741-749, 1997.
	C12	Baruch <i>et al.</i> , "The breast cancer-associated MUC1 gene generates both a receptor and its cognate binding protein," <i>Cancer Res.</i> , 59:1552-1561, 1999.
	C13	Batra <i>et al.</i> , "Transfection of the human MUC1 mucin gene into a poorly differentiated human pancreatic tumor cell line, Panc1: integration, expression and ultrastructural changes," <i>J. Cell Science</i> , 100:841-849, 1991.

25794698.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SM/

Form PTO-1449 (modified)	Atty. Docket No.: DFCI:006US	Serial No.: 10/598,295
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant: Donald W. KUFÉ Surender KHARBANDA	
	Filing Date: April 5, 2007	Group: 1635
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 3-19</i>

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C14	Bellgrau <i>et al.</i> , "A role for CD95 ligand in preventing graft rejection," <i>Nature</i> , 377:630-632, 1995.
	C15	Berger <i>et al.</i> , "Respiratory carcinoma cell lines: MUC genes and glycoconjugates," <i>American Journal of Respiratory Cell and Molecular Biology</i> , 20:500-510, 1999.
	C16	Bergeron <i>et al.</i> , "MAUB is a new mucin antigen associated with bladder cancer," <i>J. Biol. Chem.</i> , 271:6933-6940, 1996.
	C17	Beusen <i>et al.</i> , "Conformational mimicry: synthesis and solution conformation of a cyclic somatostatin hexapeptide containing a tetrazole cis amide bond surrogate," <i>Biopolymers</i> , 36:181-200, 1995.
	C18	Bird <i>et al.</i> , "Single-chain antigen-binding proteins," <i>Science</i> , 242:423-6, 1988.
	C19	Bitko <i>et al.</i> , "Inhibition of respiratory viruses by nasally administered siRNA," <i>Nature Med.</i> , 11:50-55, 2005.
	C20	Bodmer <i>et al.</i> , "Cysteine 230 is essential for the structure and activity of the cytotoxic ligand TRAIL," <i>J. Biol. Chem.</i> , 275:20632-20637, 2000.
	C21	Boldin <i>et al.</i> , "Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death," <i>Cell</i> , 85:803-815, 1996.
	C22	Brossart <i>et al.</i> , "Identification of HLA-A2-restricted T-cell epitopes derived from MUC1 tumor antigen for broadly applicable vaccine therapies," <i>Blood</i> , 93:4309-4317, 1999.
	C23	Brunner <i>et al.</i> , "pangolin encodes a Lef-1 homologue that acts downstream of Armadillo to transduce the Wingless signal in <i>Drosophila</i> ," <i>Nature</i> , 385:829-33, 1997.
	C24	Bumcrot <i>et al.</i> , "RNAi therapeutics: a potential new class of pharmaceutical drugs," <i>Nature Chemical Biology</i> , 2:711-719, 2006.
	C25	Bunz, "Cell death and cancer therapy," <i>Curr. Opin. Pharmacol.</i> , 1:337-341, 2001.
	C26	Burns and El-Deiry, "Identification of inhibitors of TRAIL-induced death (ITIDs) in the TRAIL-sensitive colon carcinoma cell line SW480 using a genetic approach," <i>J. Biol. Chem.</i> , 276:37879-37886, 2001.
	C27	Busfield <i>et al.</i> , "Characterization of a neuregulin-related gene, <i>Don-1</i> , that is highly expressed in restricted regions of the cerebellum and hippocampus," <i>Mol. Cell. Biol.</i> , 17:4007-4014, 1997.

25794698.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SM/

Form PTO-1449 (modified)		Atty. Docket No.: DFCI:006US	Serial No.: 10/598,295
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Donald W. KUFÉ Surender KHARBANDA	
		Filing Date: April 5, 2007	Group: 1635
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 3-19</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C28	Chang <i>et al.</i> , "Ligands for ErbB-family receptors encoded by a neuregulin-like gene," <i>Nature</i> , 387:509-512, 1997.
	C29	Chaudhary <i>et al.</i> , "A rapid method of cloning functional variable-region antibody genes in <i>Escherichia coli</i> as single-chain immunotoxins," <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 87:1066-70, 1990.
	C30	Ciborowski <i>et al.</i> , "Screening of anti-MUC1 antibodies for reactivity with native (ascites) and recombinant (baculovirus) MUC1 and for blocking MUC1 specific cytotoxic T-lymphocytes," <i>Tumor Biology</i> , 19:147-151, 1998.
	C31	Console <i>et al.</i> , "Antennapedia and HIV transactivator of transcription (TAT) "protein transduction domains" promote endocytosis of high molecular weight cargo upon binding to cell surface glycosaminoglycans," <i>J. Biol. Chem.</i> , 278 :35109-14, 2003.
	C32	Creagan <i>et al.</i> , "Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma," <i>J. Clin. Oncol.</i> , 17:1884-1890, 1999.
	C33	Daniel and Reynolds, "The catenin p120(ctn) interacts with Kaiso, a novel BTB/POZ domain zinc finger transcription factor," <i>Mol. Cell. Biol.</i> , 19:3614-23, 1999.
	C34	Datta <i>et al.</i> , "Overexpression of Bcl-XL by cytotoxic drug exposure confers resistance to ionizing radiation-induced internucleosomal DNA fragmentation," <i>Cell Growth Differ.</i> , 6:363-370, 1995.
	C35	Dawson <i>et al.</i> , "Synthesis of proteins by native chemical ligation," <i>Science</i> , 266:776-779, 1994.
	C36	Deng <i>et al.</i> , "TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO," <i>Genes Dev.</i> , 16:33-45, 2002.
	C37	Derossi <i>et al.</i> , "Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent," <i>J Biol. Chem.</i> , 271:18188-93, 1996.
	C38	Derossi <i>et al.</i> , "The third helix of the Antennapedia homeodomain translocates through biological membranes," <i>J Biol. Chem.</i> , 269:10444-50, 1994.
	C39	Deveraux and Reed, "IAP family proteins--suppressors of apoptosis," <i>Genes Dev.</i> , 13:239-52, 1999.
	C40	Dillman, "Antibodies as cytotoxic therapy," <i>J. Clin. Oncology</i> , 12:1497-1515, 1994.

25794698.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SM/

Form PTO-1449 (modified)		Atty. Docket No.: DFCI:006US	Serial No.: 10/598,295
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Donald W. KUFÉ Surender KHARBANDA	
		Filing Date: April 5, 2007	Group: 1635
U.S. Patent Documents See Page 1-2	Foreign Patent Documents See Page 2	Other Art See Page 3-19	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C41	Dorn <i>et al.</i> , "Down-regulation of the human tumor antigen mucin by gemcitabine on the pancreatic cancer cell line capan-2," <i>Anticancer Research</i> , 24:821-826, 2004.
	C42	Doyle, "Crystal structures of a complexed and peptide-free membrane protein-binding domain: molecular basis of peptide recognition by PDZ," <i>Cell</i> , 85:1067-76, 1996.
	C43	Drucker <i>et al.</i> , "Tamoxifen enhances apoptotic effect of cisplatin on primary endometrial cell cultures," <i>Anticancer Research</i> , 23:1549-1554, 2003.
	C44	Du <i>et al.</i> , "Smac, a Mitochondrial Protein that Promotes Cytochrome c-Dependent Caspase Activation by Eliminating IAP Inhibition," <i>Cell</i> , 102:33-42, 2000.
	C45	Dykxhoorn <i>et al.</i> , "The silent treatment: siRNAs as small molecule drugs," <i>Gene Therapy</i> , 13:541-552, 2006.
	C46	Elbashir <i>et al.</i> , "Analysis of gene function in somatic mammalian cells using small interfering RNAs," <i>Methods</i> , 26:199-213, 2002.
	C47	Elbashir <i>et al.</i> , "RNA interference is mediated by 21-and 22-nucleotide RNAs," <i>Genes and Development</i> , 15:188-200, 2001.
	C48	Elliot and O'Hare, "Intercellular trafficking and protein delivery by a herpesvirus structural protein," <i>Cell</i> , 88:223-33, 1997.
	C49	Elmqvist <i>et al.</i> , "VE-cadherin-derived cell-penetrating peptide, pVEC, with carrier functions," <i>Exp. Cell Res.</i> , 269:237-44, 2001.
	C50	Emoto <i>et al.</i> , "Proteolytic activation of protein kinase C delta by an ICE-like protease in apoptotic cells," <i>EMBO J.</i> , 14:6148-6156, 1995.
	C51	Faivre <i>et al.</i> , "Supraadditive effect of 2',2'-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines," <i>Cancer Chemother. Pharmacol.</i> , 44:117-123, 1999.
	C52	Feigl, "2,8-Dimethyl-4-(carboxymethyl)-6-(aminomethyl)phenoxathiin S-Dioxide: An Organic Substitute for the beta-Turn in Peptides," <i>J. Amer. Chem. Soc.</i> , 108:181-2, 1986.
	C53	Finn <i>et al.</i> , "MUC-1 Epithelial Tumor Mucin-Based Immunity and Cancer Vaccines," <i>Immunol. Rev.</i> , 145:61-89, 1995.
	C54	Frankel and Pabo, "Cellular uptake of the tat protein from human immunodeficiency virus," <i>Cell</i> , 55:1189-93, 1989.

25794698.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SM/

Form PTO-1449 (modified)		Atty. Docket No.: DFCI:006US	Serial No.: 10/598,295
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Donald W. KUFÉ Surender KHARBANDA	
		Filing Date: April 5, 2007	Group: 1635
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 3-19</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C55	French and Tschopp, "Inhibition of Death Receptor Signaling by FLICE-inhibitory Protein as a Mechanism for Immune Escape of Tumors," <i>J. Exp. Med.</i> , 190:891-893, 1999.
	C56	Futaki <i>et al.</i> , "Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery," <i>J. Biol. Chem.</i> , 276 :5836-40, 2001.
	C57	Geisbert <i>et al.</i> , "Postexposure Protection of Guinea Pigs against a Lethal Ebola Virus Challenge is Conferred by RNA Interference," <i>J. Infectious Diseases</i> , 193:1650-1657, 2006.
	C58	Gendler <i>et al.</i> , "A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats," <i>J. Biol. Chem.</i> , 263:12820-12823, 1988.
	C59	Gendler <i>et al.</i> , "Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin," <i>J. Biol. Chem.</i> , 265:15286-15293, 1990.
	C60	Gopalakrishnan <i>et al.</i> , "Application of Micro Arrayed Compound Screening (microARCS) to identify inhibitors of caspase-3," <i>J. Biomol. Screen</i> , 7:317-23, 2002.
	C61	Green and Loewenstein, "Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein," <i>Cell</i> , 55:1179-88, 1989.
	C62	Griffith <i>et al.</i> , "CD95-Induced Apoptosis of Lymphocytes in an Immune Privileged Site Induces Immunological Tolerance," <i>Immunity</i> , 5:7-16, 1996.
	C63	Gross <i>et al.</i> , "Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death," <i>J. Biol. Chem.</i> , 274:1156-1163, 1999.
	C64	Grzelinski <i>et al.</i> , "RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts," <i>Human Gene Therapy</i> , 17:751-766, 2006.
	C65	Haim <i>et al.</i> , "Dexamethasone, cytarabine, ifosfamide, and cisplatin as salvage therapy in Non-Hodgkin lymphoma," <i>Am. J. Clin. Oncol.</i> , 22:47-50, 1999.
	C66	Hammond <i>et al.</i> , "Post-transcriptional gene silencing by double-stranded RNA," <i>Nature Genetics</i> , 2:110-119, 2001.
	C67	Hanson <i>et al.</i> , "MUC1 expression in primary breast cancer: the effect of tamoxifen treatment," <i>Breast Cancer Research and Treatment</i> , 67:215-222, 2001.

25794698.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SM/

Form PTO-1449 (modified)		Atty. Docket No.: DFCI:006US	Serial No.: 10/598,295
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Donald W. KUFÉ Surender KHARBANDA	
		Filing Date: April 5, 2007	Group: 1635
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 3-19</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C68	Harborth <i>et al.</i> , "Identification of essential genes in cultured mammalian cells using small interfering RNAs," <i>J. Cell Science</i> , 114:4557-4565, 2001.
	C69	Harrison, "Peptide-surface association: the case of PDZ and PTB domains," <i>Cell</i> , 86:341-343, 1996.
	C70	Hartman <i>et al.</i> , "MUC1 isoform specific monoclonal antibody 6E6/2 detects preferential expression of the novel MUC1/Y protein in breast and ovarian cancer," <i>Int. J. Cancer</i> , 82:256-267, 1999.
	C71	Herr and Debatin, "Cellular stress response and apoptosis in cancer therapy," <i>Blood</i> , 98:2603-2614, 2001.
	C72	Higashiyama <i>et al.</i> , "A novel brain-derived member of the epidermal growth factor family that interacts with ErbB3 and ErbB4," <i>J. Biochem.</i> , 122:675-680, 1997.
	C73	Higgins, "Comparison of the solution conformations of a human immunodeficiency virus peptidomimetic and its retro-inverso isomer using 1H NMR spectroscopy," <i>J. Pept. Res.</i> , 50:421-35, 1997.
	C74	Hird <i>et al.</i> , "Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody," <i>Br. J. Cancer</i> , 68:403-406, 1993.
	C75	Hruby <i>et al.</i> , "Design of peptides, proteins, and peptidomimetics in chi space," <i>Biopolymers</i> , 43:219-66, 1997.
	C76	Hunt and Evans, "Till Death Us Do Part," <i>Science</i> , 293:1784-1785, 2001.
	C77	Huston <i>et al.</i> , "Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in <i>Escherichia coli</i> ," <i>Proc. Natl. Acad. Sci U.S.A.</i> , 85:5879-83, 1988.
	C78	Hymowitz <i>et al.</i> , "Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5," <i>Mol. Cell.</i> , 4:563-571, 1999.
	C79	Ikeda <i>et al.</i> , "Induction of redox imbalance and apoptosis in multiple myeloma cells by the novel triterpenoid 2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid," <i>Molecular Cancer Therapeutics</i> , 3:39-45, 2004.
	C80	Irmeler <i>et al.</i> , "Inhibition of death receptor signals by cellular FLIP," <i>Nature</i> , 388:190-195, 1997.

25794698.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SM/

Form PTO-1449 (modified)		Atty. Docket No.: DFCI:006US	Serial No.: 10/598,295
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Donald W. KUFÉ Surender KHARBANDA	
		Filing Date: April 5, 2007	Group: 1635
U.S. Patent Documents See Page 1-2	Foreign Patent Documents See Page 2	Other Art See Page 3-19	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C81	Itzkowitz <i>et al.</i> , "Sialosyl-Tn. A novel mucin antigen associated with prognosis in colorectal cancer patients," <i>Cancer</i> , 66:1960-6, 1990.
	C82	Jaattela <i>et al.</i> , "Bcl-x and Bcl-2 inhibit TNF and Fas-induced apoptosis and activation of phospholipase A2 in breast carcinoma cells," <i>Oncogene</i> , 10:2297-2305, 1995.
	C83	Jawhari <i>et al.</i> , "Up-regulated cytoplasmic expression, with reduced membranous distribution, of the src substrate p120(ctn) in gastric carcinoma," <i>J. Pathol.</i> 189:180-5, 1999.
	C84	Jen <i>et al.</i> , "Suppression of gene expression by targeted disruption of messenger RNA: available options and current strategies," <i>Stem Cells</i> , 18:307-319, 2000.
	C85	Jin <i>et al.</i> , "CIAP1 and the serine protease HTRA2 are involved in a novel p53-dependent apoptosis pathway in mammals," <i>Genes Dev.</i> , 17:359-67, 2003.
	C86	Kahn <i>et al.</i> , "Nonpeptide Mimetics of beta-Turns: A Facile Oxidative Intramolecular Cycloaddition of an Azodicarbonyl System," <i>J. Amer. Chem. Soc.</i> , 110:1638-9, 1988.
	C87	Kahn, "The design and synthesis of mimetics of peptide beta-turns," <i>J. Molec. Recognition</i> , 1:75-9, 1988.
	C88	Kalofonos <i>et al.</i> , "Kinetics, quantitative analysis and radioimmunolocalisation using indium-111-HMFG1 monoclonal antibody in patients with breast cancer," <i>Cr. J. Cancer</i> , 59:939-942, 1989.
	C89	Kalofonos <i>et al.</i> , "Radioimmunoschintigraphy in patients with ovarian cancer," <i>Acta Oncologica</i> , 38:629-634, 1999.
	C90	Karvinen <i>et al.</i> , "Homogeneous time-resolved fluorescence quenching assay (LANCE) for caspase-3," <i>J. Biomol. Screen.</i> , 7:223-31, 2002.
	C91	Kataoka <i>et al.</i> , "FLIP prevents apoptosis induced by death receptors but not by perforin/granzyme B, chemotherapeutic drugs, and gamma irradiation," <i>J. Immunol.</i> , 161:3936-3942, 1998.
	C92	Kayagaki <i>et al.</i> , "Metalloproteinase-mediated release of human Fas ligand," <i>J. Exp. Med.</i> , 182:1777-1783, 1995.
	C93	Kemp and Stites, "A convenient preparation of derivatives of 3(s)-amino-109(r)-carboxy-1,6-diazacyclodeca-2,7-dione the dilactam of L-alpha,gamma-diaminobutyric acid and d-glutamic acid: a beta-turn template," <i>Tet. Lett.</i> , 29:5057-60, 1988.

25794698.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SM/

Form PTO-1449 (modified)		Atty. Docket No.: DFCI:006US	Serial No.: 10/598,295
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Donald W. KUFÉ Surender KHARBANDA	
		Filing Date: April 5, 2007	Group: 1635
U.S. Patent Documents See Page 1-2	Foreign Patent Documents See Page 2	Other Art See Page 3-19	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C94	Kennerdell <i>et al.</i> , "Heritable gene silencing in <i>Drosophila</i> using double-stranded RNA," <i>Nature Biotechnology</i> , 17:896-898, 2000.
	C95	Kharbanda <i>et al.</i> , "Nuclear signaling induced by ionizing radiation involves colocalization of the activated p56/p53lyn tyrosine kinase with p34cdc2," <i>Cancer Res.</i> , 56:3617-3621, 1996.
	C96	Kim <i>et al.</i> , "Cholesteryl oligoarginine delivering vascular endothelial growth factor siRNA effectively inhibits tumor growth in colon adenocarcinoma," <i>Molecular Therapy</i> , 14:343-350, 2006.
	C97	Kischkel <i>et al.</i> , "Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor," <i>EMBO J.</i> , 14:5579-5588, 1995.
	C98	Kluck <i>et al.</i> , "The Release of Cytochrome c from Mitochondria: A Primary Site for BCL-2 Regulation of Apoptosis," <i>Science</i> , 275:1132-1136, 1997.
	C99	Kondo <i>et al.</i> , "Decreased MUC1 expression induces E-Cadherin-mediated cell adhesion of breast cancer cell lines," <i>Cancer Research</i> , 58:2014-2019, 1998.
	C100	Kroemer and Reed, "Mitochondrial control of cell death," <i>Nat. Med.</i> , 6:513-519, 2000.
	C101	Kufe <i>et al.</i> , "Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors," <i>Hybridoma</i> , 3:223-232, 1984.
	C102	Kumar <i>et al.</i> , "Abrogation of the cell death response to oxidative stress by the c-Abl tyrosine kinase inhibitor STI571," <i>Mol. Pharmacol.</i> , 63:276-282, 2003.
	C103	Kuppuswamy <i>et al.</i> , "Multiple functional domains of Tat, the trans-activator of HIV-1, defined by mutational analysis," <i>Nucl. Acids Res.</i> , 17:3551-61, 1989.
	C104	LaVallee <i>et al.</i> , "2-Methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway," <i>Cancer Research</i> , 63:468-475, 2003.
	C105	LeBlanc <i>et al.</i> , "Tumor-cell resistance to death receptor--induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax," <i>Nat. Med.</i> , 8:274-281, 2002.
	C106	Lewis <i>et al.</i> , "Efficient delivery of siRNA for inhibition of gene expression in postnatal mice," <i>Nature Genetics</i> , 32:107-108, 2002.
	C107	Li and Kufe, "The human DF3/MUC1 carcinoma-associated antigen signals nuclear localization of the catenin p120 ^{cas} ," <i>Biochem. Biophys. Res. Commun.</i> , 281:440-443, 2001.

25794698.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SM/

Form PTO-1449 (modified)		Atty. Docket No.: DFCI:006US	Serial No.: 10/598,295
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Donald W. KUFÉ Surender KHARBANDA	
		Filing Date: April 5, 2007	Group: 1635
U.S. Patent Documents See Page 1-2	Foreign Patent Documents See Page 2	Other Art See Page 3-19	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C108	Li <i>et al.</i> , "Cleavage of BID by Caspase 8 Mediates the Mitochondrial Damage in the FAS Pathway of Apoptosis," <i>Cell</i> , 94:491-501, 1998.
	C109	Li <i>et al.</i> , "Cytochrome c and dATP-Dependent Formation of Apaf-1/Caspase-9 Complex initiates and Apoptotic Protease Cascade," <i>Cell</i> , 91:479-489, 1997.
	C110	Li <i>et al.</i> , "DF3/MUC1 signaling in multiple myeloma cells is regulated by interleukin-7," <i>Cancer Biol. Ther.</i> , 2:187-193, 2003.
	C111	Li <i>et al.</i> , "Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent on the DF3/MUC1 oncoprotein," <i>Mol. Cancer Res.</i> , 1:765-775, 2003.
	C112	Li <i>et al.</i> , "Human DF3/MUC1 carcinoma-associated protein functions as an oncogene," <i>Oncogene</i> , 22:6107-6110, 2003.
	C113	Li <i>et al.</i> , "Interaction of glycogen synthase kinase 3 β with the DF3/MUC1 carcinoma-associated antigen and β -catenin," <i>Mol. Cell. Biol.</i> , 18:7216-7224, 1998.
	C114	Li <i>et al.</i> , "The c-Src tyrosine kinase regulates signaling of the human DF3/MUC1 carcinoma-associated antigen with GSK3 β and β -catenin," <i>J. Biol. Chem.</i> , 276:6061-6064, 2001.
	C115	Li <i>et al.</i> , "The EGF receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-SRC and β -catenin," <i>JBC Papers in Press</i> , manuscript C100359200, August 1, 2001.
	C116	Li <i>et al.</i> , "The epidermal growth factor receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-Src and beta-catenin," <i>J. Biol. Chem.</i> , 276:35236-42, 2001.
	C117	Li <i>et al.</i> , "Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque," <i>Nature Med.</i> , 11:944-951, 2005.
	C118	Ligtenberg <i>et al.</i> , "Cell associated episialin is a complex containing two proteins derived from a common precursor," <i>J. Biol. Chem.</i> , 267:6171-6177, 1992.
	C119	Ligtenberg <i>et al.</i> , "Suppression of Cellular Aggregation by High Levels of Episialin," <i>Cancer Res.</i> , 52:2318-2324, 1992.
	C120	Lin <i>et al.</i> , "Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence," <i>J. Biol. Chem.</i> , 270:14255-8, 1995.
	C121	Liu <i>et al.</i> , "Identification of a functionally important sequence in the cytoplasmic tail of integrin beta 3 by using cell-permeable peptide analogs," <i>Proc. Natl Acad. Sci. U.S.A.</i> , 93 :11819-24, 1996.

25794698.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SM/

Form PTO-1449 (modified)		Atty. Docket No.: DFCI:006US	Serial No.: 10/598,295
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Donald W. KUFÉ Surender KHARBANDA	
		Filing Date: April 5, 2007	Group: 1635
U.S. Patent Documents See Page 1-2	Foreign Patent Documents See Page 2	Other Art See Page 3-19	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C122	Liu <i>et al.</i> , "Induction of Apoptotic Program in Cell-Free Extracts: Requirement of dATP and Cyochrome c," <i>Cell</i> , 86:147-157, 1996.
	C123	Luo <i>et al.</i> , "An efficient intrathecal delivery of small interfering RNA to the spinal cord and peripheral neurons," <i>Molecular Pain</i> , 1:29, 2005.
	C124	Luo <i>et al.</i> , "Bid, A Bcl2 Interacting Protein, Mediates Cytochrome c Release from Mitochondria in Response to Activation of Cell Surface Death Receptors," <i>Cell</i> , 94:481-490, 1998.
	C125	Makimura <i>et al.</i> , "Reducing hypothalamic AGRP by RNA interference increases metabolic rate and decreases body weight without influencing food intake," <i>BMC Neuroscience</i> , 3:18, 2002.
	C126	Maraveyas <i>et al.</i> , "Pharmacokinetics and toxicity of an Yttrium-90-CITC-DTPA-HMFG1 radioimmunoconjugate for intraperitoneal radioimmunotherapy of ovarian cancer," <i>Cancer</i> , 73:1067-1075, 1994.
	C127	Maraveyas <i>et al.</i> , "Pharmacokinetics, biodistribution, and dosimetry of specific and control radiolabeled monoclonal antibodies in patients with primary head and neck squamous cell carcinoma," <i>Cancer Research</i> , 55:1060-1069, 1995.
	C128	Mariani <i>et al.</i> , "Regulation of cell surface APO-1/Fas (CD95) ligand expression by metalloproteases," <i>Eur. J. Immunol.</i> , 25:2303-2307, 1995.
	C129	Marsters <i>et al.</i> , "A novel receptor for Apo2L/TRAIL contains a truncated death domain," <i>Curr. Biol.</i> , 7:1003-1006, 1997.
	C130	Martinez <i>et al.</i> , "Single-stranded antisense siRNAs guide target RNA cleavage in RNAi," <i>Cell</i> , 110:563-574, 2002.
	C131	Martins, "The serine protease Omi/HtrA2: a second mammalian protein with a Reaper-like function," <i>Cell Death Diff.</i> , 9:699-701, 2002.
	C132	McGuckin <i>et al.</i> , "Prognostic significance of MUC1 epithelial mucin expression in breast cancer," <i>Human Pathology</i> , 26:432-439, 1995.
	C133	Mi <i>et al.</i> , "Characterization of a class of cationic peptides able to facilitate efficient protein transduction in vitro and in vivo," <i>Mol. Ther.</i> , 2:339-47, 2000.
	C134	Milik <i>et al.</i> , "Lung lymphocyte elimination by apoptosis in the murine response to intratracheal particulate antigen," <i>J. Clin. Invest.</i> , 99:1082-1091, 1997.

25794698.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SM/

Form PTO-1449 (modified)		Atty. Docket No.: DFCI:006US	Serial No.: 10/598,295
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Donald W. KUFÉ Surender KHARBANDA	
		Filing Date: April 5, 2007	Group: 1635
U.S. Patent Documents See Page 1-2	Foreign Patent Documents See Page 2	Other Art See Page 3-19	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C135	Minakuchi <i>et al.</i> , "Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo," <i>Nucleic Acids Research</i> , 32:e109, 2004.
	C136	Molenaar <i>et al.</i> , XTcf-3 transcription factor mediates beta-catenin-induced axis formation in <i>Xenopus</i> embryos," <i>Cell</i> , 86:391-9, 1996.
	C137	Morris <i>et al.</i> , "A new peptide vector for efficient delivery of oligonucleotides into mammalian cells," <i>Nucleic Acid Res.</i> , 25:2730-6, 1997.
	C138	Muzio <i>et al.</i> , "FLICE, A Novel FADD-Homologous ICE/CED-3-like Protease, Is Recruited to the CD95 (fas/APO-1) Death-Inducing Signaling Complex," <i>Cell</i> , 85:817-827, 1996.
	C139	Nagai and Sato, "Synthesis of a bicyclic dipeptide with the shape of beta-turn central part," <i>Tet. Lett.</i> , 26:647-50, 1985.
	C140	Nagata, "Apoptosis by Death Factor," <i>Cell</i> , 88:355-365, 1997.
	C141	Nakamura <i>et al.</i> , "RNA interference targeting transforming growth factor-beta type II receptor suppresses ocular inflammation and fibrosis," <i>Molecular Vision</i> , 10:703-711, 2004.
	C142	Nakashima <i>et al.</i> , "Inhibition of angiogenesis by a new isocoumarin, NM-3," <i>J. Antibiotics</i> , 52:426-428, 1999.
	C143	Nicholson <i>et al.</i> , "Radioimmunotherapy after chemotherapy compared to chemotherapy alone in the treatment of advanced ovarian cancer: a matched analysis," <i>Oncology Reports</i> 5:223-226, 1998.
	C144	Niethammer <i>et al.</i> , "CRIPT, a novel postsynaptic protein that binds to the third PDZ domain of PSD-95/SAP90," <i>Neuron</i> , 20:693-707, 1989.
	C145	Niu <i>et al.</i> , "Inhibition of HPV 16 E6 oncogene expression by RNA interference in vitro and in vivo," <i>Int. J. Gynecol. Cancer</i> , 16:743-751, 2006.
	C146	Novak and Dedhar, "Signaling through beta-catenin and Lef/Tcf," <i>Cell Mol. Life Sci.</i> , 523-37, 1999.
	C147	Obermair <i>et al.</i> , "Expression of MUC1 splice variants in benign and malignant ovarian tumours," <i>Int. J. Cancer</i> , 100:166-171, 2002.
	C148	Oehlke <i>et al.</i> , "Cellular uptake of an alpha-helical amphipathic model peptide with the potential to deliver polar compounds into the cell interior non-endocytically," <i>Biochim. Biophys. Acta.</i> , 1414: 127-39, 1998.

25794698.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SM/

Form PTO-1449 (modified)		Atty. Docket No.: DFCI:006US	Serial No.: 10/598,295
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Donald W. KUFÉ Surender KHARBANDA	
		Filing Date: April 5, 2007	Group: 1635
U.S. Patent Documents See Page 1-2	Foreign Patent Documents See Page 2	Other Art See Page 3-19	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C149	Okazaki <i>et al.</i> , "Downregulation of gastric mucin gene expression and its biosynthesis by dexamethasone in the human," <i>J. Clin. Gastroenterol.</i> , 27(suppl. 1):S91-S92, 1998.
	C150	Opalinska <i>et al.</i> , "Nucleic-acid therapeutics: basic principles and recent applications," <i>Nature Reviews Drug Discovery</i> , 1:503-514, 2002.
	C151	Padrón <i>et al.</i> , "Selective cell kill of the combination of gemcitabine and cisplatin in multilayered postconfluent tumor cell cultures," <i>Anti-Cancer Drugs</i> , 10:445-452, 1999.
	C152	Palliser <i>et al.</i> , "An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection," <i>Nature</i> , 439:89-94, 2006.
	C153	Pan <i>et al.</i> , "An Antagonist Decoy Receptor and a Death Domain-Containing Receptor for TRAIL," <i>Science</i> , 277:815-818, 1997.
	C154	Pan <i>et al.</i> , "The Receptor for the Cytotoxic Ligand TRAIL," <i>Science</i> , 276:111-113, 1997.
	C155	Parrish <i>et al.</i> , "Functional anatomy of a dsRNA trigger: differential requirement for the two trigger strands in RNA interference," <i>Molecular Cell</i> , 8:1077-1087, 2000.
	C156	Paszkiewicz-Gadek <i>et al.</i> , "Biosynthesis of MUC1 mucin in human endometrial adenocarcinoma is modulated by estradiol and tamoxifen," <i>Gynecol. Endocrinol.</i> , 17:37-44, 2003.
	C157	Pavlovic <i>et al.</i> , "Targeting of non-small cell lung cancer using HMFG1- ^{99m} TC monoclonal antibodies," <i>Med Pregl.</i> , 46 Suppl 1:26-28, 1993
	C158	Perey <i>et al.</i> , "Tumor selective reactivity of a monoclonal antibody prepared against a recombinant peptide derived from the DF3 human breast carcinoma-associated antigen," <i>Cancer Research</i> , 52:2563-2568, 1992.
	C159	Perez <i>et al.</i> , "Antennapedia homeobox as a signal for the cellular internalization and nuclear addressing of a small exogenous peptide," <i>J. Cell. Sci.</i> , 102:717-22, 1992.
	C160	Pescarolo <i>et al.</i> , "A retro-inverso peptide homologous to helix 1 of c-Myc is a potent and specific inhibitor of proliferation in different cellular systems," <i>FASEB J.</i> , 15:31-3, 2001.
	C161	Pitti <i>et al.</i> , "Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family," <i>J. Biol. Chem.</i> , 271:12687-12690, 1996.
	C162	Pooga <i>et al.</i> , "Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo," <i>Nature Biotech.</i> , 16 :857-61, 1998.

25794698.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SM/

Form PTO-1449 (modified)		Atty. Docket No.: DFCI:006US	Serial No.: 10/598,295
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Donald W. KUFÉ Surender KHARBANDA	
		Filing Date: April 5, 2007	Group: 1635
U.S. Patent Documents See Page 1-2	Foreign Patent Documents See Page 2	Other Art See Page 3-19	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C163	Porowska <i>et al.</i> , "MUC1 expression in human breast cancer cells is altered by the factors affecting cell proliferation," <i>Neoplasma</i> , 49:104-109, 2002.
	C164	Price <i>et al.</i> , "Summary report on the ISOBM TD-4 workshop: analysis of 56 monoclonal antibodies against the MUC1 mucin," San Diego, California, November 17-23, 1996, <i>Tumor Biol.</i> , 19:sup. 1:1-20, 1998.
	C165	Reddish <i>et al.</i> , "Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy," <i>Cancer Immunol. Immunother.</i> , 42:303-9, 1996.
	C166	Reich <i>et al.</i> , "Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model," <i>Molecular Vision</i> , 9:210-216, 2003.
	C167	Ren <i>et al.</i> , "Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents," <i>Cancer Cell</i> , 5:163-175, 2004.
	C168	Ren <i>et al.</i> , "Protein kinase C delta regulates function of the DF3/MUC1 carcinoma antigen in beta-catenin signaling," <i>J. Biol. Chem.</i> , 277:17616-17622, 2002.
	C169	Reynolds <i>et al.</i> , "Identification of a new catenin: the tyrosine kinase substrate p120cas associates with E-cadherin complexes," <i>Mol. Cell. Biol.</i> , 14:8333-42, 1994.
	C170	Reynolds <i>et al.</i> , "Transformation-specific tyrosine phosphorylation of a novel cellular protein in chicken cells expressing oncogenic variants of the avian cellular src gene," <i>Mol. Cell. Biol.</i> , 9:629-38, 1989.
	C171	Rondinone, "Therapeutic potential of rna in metabolic diseases," <i>BioTechniques</i> , 40:S31-S36, 2006.
	C172	Rousselle <i>et al.</i> , "New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy," <i>Mol. Pharmacol.</i> , 57:679-86, 2000.
	C173	Ruben <i>et al.</i> , "Structural and functional characterization of human immunodeficiency virus tat protein," <i>J. Virol.</i> , 63(1):1-8, 1989.
	C174	Sato <i>et al.</i> , "FAP-1: A Protein Tyrosine Phosphatase That Associates with Fas," <i>Science</i> , 268:411-415, 1995.
	C175	Scaffidi <i>et al.</i> , "Differential Modulation of Apoptosis Sensitivity in CD95 Type I and Type II Cells," <i>J. Biol. Chem.</i> , 274:22532-22538, 1999.

25794698.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SM/

Form PTO-1449 (modified)		Atty. Docket No.: DFCI:006US	Serial No.: 10/598,295
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Donald W. KUFÉ Surender KHARBANDA	
		Filing Date: April 5, 2007	Group: 1635
U.S. Patent Documents See Page 1-2	Foreign Patent Documents See Page 2	Other Art See Page 3-19	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C176	Schiffelers <i>et al.</i> , "Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle," <i>Nucleic Acids Research</i> , 32:e149, 2004.
	C177	Schneider <i>et al.</i> , "Mutagenesis and selection of PDZ domains that bind new protein targets," <i>Nat. Biotech.</i> , 17:170-5, 1998.
	C178	Schultz <i>et al.</i> , "Specific interactions between the syntrophin PDZ domain and voltage-gated sodium channels," <i>Nat. Struct. Biol.</i> , 5:19-24, 1998.
	C179	Schumacher <i>et al.</i> , "Immunoscintigraphy with positron emission tomography: Gallium-68 chelate imaging of breast cancer pretargeted with bispecific anti-MUC1/anti-Ga chelate antibodies," <i>Cancer Research</i> , 61:3712-3717, 2001.
	C180	Shen <i>et al.</i> , "Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1," <i>Gene Therapy</i> , 13:225-234, 2006.
	C181	Shimazui <i>et al.</i> , "Prognostic value of cadherin-associated molecules (alpha-, beta-, and gamma-catenins and p120cas) in bladder tumors," <i>Cancer Res.</i> , 56:4154-8, 1996.
	C182	Siddiqui <i>et al.</i> , "Isolation and sequencing of a cDNA coding for the human DF3 breast carcinoma-associated antigen," <i>Proc. Natl. Acad. Sci. USA</i> , 85:2320-2323, 1988.
	C183	Smith and Waterman, "Comparison of Biosequences," <i>Adv. Appl. Math.</i> , 2:482-9, 1981.
	C184	Smith, "Design, Synthesis, and Crystal Structure of a Pyrrolinon-Based Peptidomimetic Possessing the Conformation of a beta-Strand: Potential Application to the Design of Novel Inhibitors of Proteolytic Enzymes," <i>J. Amer. Chem. Soc.</i> , 114:10672-4, 1992.
	C185	Snyder <i>et al.</i> , "Treatment of Terminal Peritoneal Carcinomatosis by a Transducible p53-Activating peptide," <i>PLoS Biology</i> , 2:186-93, 2004.
	C186	Songyang <i>et al.</i> , "Recognition of unique carboxyl-terminal motifs by distinct PDZ domains," <i>Science</i> , 275:73-7, 1997.
	C187	Soomets <i>et al.</i> , "Deletion analogues of transportin," <i>Biochim. Biophys. Acta</i> , 1467:165-176, 2000.
	C188	Soutschek <i>et al.</i> , "Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs," <i>Nature</i> , 432:173-178, 2004.
	C189	Spatola, "A Peptide Backbone Modifications," In: <i>Chemistry and Biochemistry of Amino Acids, Peptides and Proteins</i> , 7:267-357, Marcell Dekker, NY, 1983.

25794698.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SM/

Form PTO-1449 (modified)		Atty. Docket No.: DFCI:006US	Serial No.: 10/598,295
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Donald W. KUFÉ Surender KHARBANDA	
		Filing Date: April 5, 2007	Group: 1635
U.S. Patent Documents See Page 1-2	Foreign Patent Documents See Page 2	Other Art See Page 3-19	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C190	Srinivasan <i>et al.</i> , "Bcl-xL functions downstream of caspase-8 to inhibit Fas- and tumor necrosis factor receptor 1-induced apoptosis of MCF7 breast carcinoma cells," <i>J. Biol. Chem.</i> , 273:4523-4529, 1998.
	C191	Srinivasula <i>et al.</i> , "Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization," <i>Mol. Cell.</i> , 1:949-957, 1998.
	C192	Stennicke <i>et al.</i> , "Pro-caspase-3 is a major physiologic target of caspase-8," <i>J. Biol. Chem.</i> , 273:27084-27090, 1998.
	C193	Strous and Decker, "Mucin-Type Glycoproteins," <i>Crit. Rev. Biochem., Mol. Biol.</i> , 27:57-92, 1992.
	C194	Subbarao <i>et al.</i> , "pH-dependent bilayer destabilization by an amphipathic peptide," <i>Biochemistry</i> , 26:2964-2972, 1987.
	C195	Takei <i>et al.</i> , "A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics," <i>Cancer Research</i> , 64:3365-3370, 2004.
	C196	Takeichi, "Cadherins: a molecular family important in selective cell-cell adhesion," <i>Annu. Rev. Biochem.</i> , 59:237-52, 1990.
	C197	Taylor <i>et al.</i> , "Antisense oligonucleotides: a systematic high-throughput approach to target validation and gene function determination," <i>Drug Discovery Today</i> , 4:562-567, 1999.
	C198	Thakker <i>et al.</i> , "siRNA-mediated knockdown of the serotonin transporter in the adult mouse brain," <i>Molecular Psychiatry</i> , 10:782-789, 2005.
	C199	Timmer <i>et al.</i> , "Fas receptor-mediated apoptosis: a clinical application?" <i>J. Pathol.</i> , 196:125-134, 2002.
	C200	Tondini <i>et al.</i> , "Evaluation of monoclonal antibody DF3 conjugated with ricin as a specific immunotoxin for <i>in Vitro</i> purging of human bone marrow," <i>Cancer Research</i> , 50:1170-1175, 1990.
	C201	Topp <i>et al.</i> , "MUC-1 specific T-cells are present in multiple myeloma patients at high frequency after allogeneic transplantation buy may not mediated the graft versus myeloma effect," <i>Blood</i> , 100: page Abstract No. 5191, 2002.
	C202	Torchilin and Levchenko, "TAT-liposomes: a novel intracellular drug carrier," <i>Curr. Protein Pept. Sci.</i> , 4:133-40, 2003.

25794698.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SM/

Form PTO-1449 (modified)		Atty. Docket No.: DFCI:006US	Serial No.: 10/598,295
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Donald W. KUFÉ Surender KHARBANDA	
		Filing Date: April 5, 2007	Group: 1635
U.S. Patent Documents See Page 1-2	Foreign Patent Documents See Page 2	Other Art See Page 3-19	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C203	Tseng <i>et al.</i> , "Translocation of liposomes into cancer cells by cell-penetrating peptides penetratin and tat: a kinetic and efficacy study," <i>Mol. Pharmacol.</i> , 62:864-72, 2002.
	C204	Urban-Klein <i>et al.</i> , "RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo," <i>Gene Therapy</i> , 12:461-466, 2005.
	C205	van Hof <i>et al.</i> , "Biodistribution of 111Indium-labeled engineered human antibody CTMO1 in ovarian cancer patients: influence of protein dose," <i>Cancer Research</i> , 56:5179-5185, 1996.
	C206	Verhagen <i>et al.</i> , "Identification of DIABLO, a Mammalian Protein that Promotes Apoptosis by Binding to and Antagonizing IAP Proteins," <i>Cell</i> , 102:43-53, 2000.
	C207	Vermeer <i>et al.</i> , "Segregation of receptor and ligand regulates activation of epithelial growth factor receptor," <i>Nature</i> , 422:322-326, 2003.
	C208	Vives <i>et al.</i> , "A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus," <i>J. Biol. Chem.</i> , 272 :16010-7, 1997.
	C209	Walczak <i>et al.</i> , "TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL," <i>EMBO J.</i> , 16:5386-5397, 1997.
	C210	Walczak <i>et al.</i> , "Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo," <i>Nat. Med.</i> , 5:157-163, 1999.
	C211	Walsh <i>et al.</i> , "Heterogeneity of MUC1 expression by human breast carcinoma cell lines <i>in vivo</i> and <i>in vitro</i> ," <i>Breast Cancer Research and Treatment</i> , 58:255-266, 2000.
	C212	Wang and El-Deiry, "TRAIL and apoptosis induction by TNF-family death receptors," <i>Oncogene</i> , 24:8628-8633, 2003.
	C213	Wei <i>et al.</i> , "MUC1 oncoprotein stabilizes and activates estrogen receptor α ," <i>Molecular Cell</i> , 21:295-305, 2006.
	C214	Wender <i>et al.</i> , "The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters," <i>Proc. Natl. Acad. Sci., U.S.A.</i> , 97:13003-8, 2000.
	C215	Williams <i>et al.</i> , "Selective inhibition of growth factor-stimulated mitogenesis by a cell-permeable Grb2-binding peptide," <i>J. Biol. Chem.</i> , 272:22349-54, 1997.

25794698.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SM/

Form PTO-1449 (modified)		Atty. Docket No.: DFCI:006US	Serial No.: 10/598,295
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Donald W. KUFÉ Surender KHARBANDA	
		Filing Date: April 5, 2007	Group: 1635
U.S. Patent Documents See Page 1-2	Foreign Patent Documents See Page 2	Other Art See Page 3-19	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C216	Wreschner <i>et al.</i> , "Does a novel form of the breast cancer marker protein MUC1, act as receptor molecule that modulates signal transduction," In: <i>Antigen and Antibody Molecular Engineering in Breast Cancer Diagnosis and Treatment</i> , Ed. Ceriani Plenum Press, New York, pp. 17-26, 1994.
	C217	Xia <i>et al.</i> , "siRNA-mediated gene silencing in vitro and invivo," <i>Nature Biotechnology</i> , 20:1006-1010, 2002.
	C218	Yamamoto <i>et al.</i> , "Interaction of the DF3/MUC1 breast carcinoma-associated antigen and beta-catenin in cell adhesion," <i>J. Biol. Chem.</i> , 272:12492-4, 1997.
	C219	Yang <i>et al.</i> , "Prevention of Apoptosis by Bcl-2: Release of Cytochrome c from Mitochondria Blocked," <i>Science</i> , 275:1129-1132, 1997.
	C220	Zimmerman <i>et al.</i> , "RNAi-mediated gene silencing in non-human primates," <i>Nature</i> , 441:111-114, 2006.
	C221	Zrihan-Licht <i>et al.</i> , "Characterization and molecular cloning of a novel MUC1 protein, devoid of tandem repeats, expressed in human breast cancer tissue," <i>Eur. J. Biochem.</i> , 224:787-795, 1994.
	C222	Zrihan-Licht <i>et al.</i> , "Tyrosine phosphorylation of the MUC1 breast cancer membrane proteins: cytokine receptor-like molecules," <i>FEBS Let.</i> , 356:130-136, 1994.

25794698.1

EXAMINER: /Sean McGarry/	DATE CONSIDERED: 06/17/2009
EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SM/